A redesigned cancer immunotherapy is showing striking early results after decades of disappointment with similar drugs. Researchers engineered a more powerful CD40 agonist antibody and changed how it’s delivered—injecting it directly into tumors instead of into the bloodstream. In a small clinical trial of 12 patients with metastatic cancers, six saw their tumors shrink and two experienced complete remission.
source https://www.sciencedaily.com/releases/2026/03/260315225121.htm
'Double-edged' nature of workplace resilience examined
-
From underdog stories to comeback victories, everyone loves a tale of
perseverance. But a new study suggests that highlighting workplace
resilience can som...
1 day ago
No comments:
Post a Comment